Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
ElevateBio logo — A cell and gene therapy company accelerating access to techn...

ElevateBio

A cell and gene therapy company accelerating access to technologies and expertise to change the future of medicine.

Founded 2021 United States Waltham, United States 494 employees Series D Total: $1.25B Biotechnology

General Information

Company Name ElevateBio
Founded Year 2021
Location United States Waltham, United States +1
Employees 494
Industries Biotechnology
Funding Stage Series D
Social

Get notified when ElevateBio moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

AI Insight

Bounce Watch AI
2 months ago

ElevateBio is demonstrating robust strategic momentum, marked by the recent launch of a new epigenetic editing platform and the upcoming presentation of a targeted insertion platform at CRISPR2026. These developments underscore the company's continuous innovation and expansion of its proprietary gene editing technologies. Furthermore, a strategic partnership with Kyverna Therapeutics for CAR T-cell therapy manufacturing highlights the strong demand for ElevateBio's CDMO capabilities and its role in advancing life-transforming therapies towards commercialization.

Signal Types
Product Launch Partnership Event Participation
Strategic Labels
Product Innovation CDMO Expansion Technology Leadership
Next Move: Commercialization
·
Impact: 8/10
·
Ideal For: Advanced Therapy CDMO Investors - Growth Stage

About ElevateBio

ElevateBio is a biotechnology startup that aims to revolutionize medicine by accelerating access to cutting-edge cell and gene therapy technologies. The company, founded in 2021 and headquartered in the United States, has quickly gained attention in the industry. ElevateBio boasts a robust team of industry-leading talent and has established state-of-the-art facilities to drive the development and commercialization of transformative therapies. Its integrated technology platforms, including gene editing and induced pluripotent stem cells, are paving the way for innovative medical solutions. ElevateBio's groundbreaking BaseCamp is a purpose-built manufacturing platform that offers process innovation and Good Manufacturing Practice capabilities, enabling the production of viral vectors, RNA, and cell therapies. The recently secured $14.00M in Angel Round investment on 23 March 2021 from Qiming Venture Partners speaks to the confidence that industry insiders have in the company's potential. ElevateBio is rapidly expanding its collaborations with industry partners and selectively developing its portfolio of cellular and genetic medicines. With its team of forward-thinking scientists and drug developers, ElevateBio is blurring the boundaries between technology and healthcare, redefining the notion of a technology company in drug development. Their efforts are poised to make a profound impact on the future of medicine.

Taxonomy: cell and gene therapy, technology-driven company, innovation, commercialization, gene editing, induced pluripotent stem cells (iPSCs), protein engineering, vector engineering, cellular engineering, manufacturing platform, process innovation, drug development, collaborations

Funding Rounds & Investors (5)

View All
Funding Stage Amount Investors Lead Investors Date
Series D •••••• 18
Investor Investor Investor Investor Investor Investor Investor Investor Investor Investor Investor Investor Investor Investor
•••• •••• 		01 May 2023
Series C •••••• 10
Investor Investor Investor Investor Investor Investor Investor Investor
•••• •••• 		01 Mar 2021
Series B •••••• 9
Investor Investor Investor Investor Investor Investor Investor Investor
•••• •••• 		01 Mar 2020
Series A •••••• 5
Investor Investor Investor Investor
•••• •••• 		01 Jun 2019
Series A •••••• - 01 Jan 2018

ElevateBio Alternatives & Competitors

ElevateBio vs
Nanotransfer
Nanotransfer Argentina

Developing the next generation delivery system for gene therapies

Pre Seed
6 employees
Biotechnology, Health Care
Compare ElevateBio vs Nanotransfer
ElevateBio vs
Basilard BioTech, Inc.
Basilard BioTech, Inc. United States

Nanomechanical Gene Delivery to Transform the Engineering of Cell Based Therapies

Seed
5 employees
Biopharma, Biotechnology
Compare ElevateBio vs Basilard BioTech, Inc.
ElevateBio vs
Refuge Biotechnologies
Refuge Biotechnologies United States

DESIGNING INTELLIGENT CELL THERAPIES TO FIGHT CANCER

Series B
3 employees
Biotechnology, Health Care
Compare ElevateBio vs Refuge Biotechnologies

FAQ About ElevateBio

A cell and gene therapy company accelerating access to technologies and expertise to change the future of medicine.
ElevateBio was founded in 2021.
ElevateBio is headquartered in Waltham, United States.
ElevateBio operates in the following industries: Biotechnology.
ElevateBio has approximately 494 employees.
ElevateBio has completed 5 funding rounds, raising a total of $1.25B. The latest funding stage is Series D.
Top alternatives and competitors to ElevateBio include Nanotransfer, Basilard BioTech, Inc., Refuge Biotechnologies, CellFE, VintaBio. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
ElevateBio and Nanotransfer are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors ElevateBio and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy